John Walter Hanna Jr., president and chief executive officer of CareDx, Inc. (NASDAQ: CDNA), sold 10,282 shares of the company's common stock on April 16, 2026. The sale generated proceeds of $217,155, with shares transacted at $21.12 apiece.
The disposition was executed under a Rule 10b5-1 trading plan that Mr. Hanna Jr. established on December 13, 2024. The timing of the sale coincided with a recent run-up in CareDx shares - the stock rose 27% over the prior week and was up roughly 41% over the last six months, trading at $21.32.
After completing this transaction, Mr. Hanna Jr. directly holds 676,475 shares of CareDx common stock.
Independent valuation commentary noted in market coverage indicates the stock appears slightly overvalued at current levels based on Fair Value metrics. That assessment is presented within InvestingPro's analysis framework, which is available through its Pro Research Report alongside additional analyst tips.
CareDx has been active on several fronts beyond insider activity. The company reported stronger fourth-quarter results, with revenue increasing by 25%. Management attributed that top-line growth to a 17% increase in volume and a 5% rise in average selling prices. For 2026, CareDx issued revenue guidance calling for growth between 11% and 17% - a range that the company says exceeds estimates from BTIG and consensus forecasts.
In response to the results and guidance, BTIG raised its price target on CareDx to $26 while maintaining a Buy rating.
Strategic portfolio moves continued with a definitive agreement to sell the Lab Products business to EuroBio Scientific for $170 million in cash. CareDx described the unit as encompassing in vitro diagnostic PCR kits and next-generation sequencing (NGS)-based kits used in transplant-related applications.
On the product and technology front, CareDx introduced VANTx, a cloud-based artificial intelligence platform aimed at transplant research. The company said the platform is designed to assist clinicians and pharmaceutical partners with data analysis and clinical trial design.
Leadership changes were also disclosed: Keith Kennedy, who served as chief operating officer, has been named chief financial officer with expanded responsibility to oversee the finance organization.
Collectively, these developments - executive share sales, robust quarterly performance, forward guidance, a divestiture of a diagnostics business, an AI product launch and a finance leadership change - outline a period of active operational and strategic activity at CareDx.